| Gene symbol | MSLN | Synonyms | MPF, SMRP | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | mesothelin | ||||
| GTO ID | GTC3108 |
| Trial ID | NCT05451849 |
| Disease | Lung Non-Small Cell Carcinoma | Colorectal Carcinoma | Peritoneal Mesothelioma | Mesothelioma | Triple-Receptor Negative Breast Cancer | Malignant Mesothelioma | Ovarian Cancer | Ovarian Melanoma | Pancreatic Cancer | Ovarian Serous Cystadenocarcinoma | Pancreatic Adenocarcinoma | Colorectal Cancer | Cholangiocarcinoma | Mesotheliomas Pleural |
| Altered gene | MSLN |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TC-510|MSLN TCR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer |
| Year | 2022 |
| Country | United States |
| Company sponsor | TCR2 Therapeutics |
| Other ID(s) | TCR2-21-01 |
| Cohort 1 | |||||||||
|
|||||||||